NIHON PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 1921-08-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.nihon-pharm.co.jp
Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Nihon Pharmaceutical Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT05177939
- Locations
- 🇯🇵
Trial site 1, Ube, Yamaguchi, Japan
Study of NPO-13 During Colonoscopy
Phase 2
Completed
- Conditions
- Bowel Disease
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- Nihon Pharmaceutical Co., Ltd
- Target Recruit Count
- 158
- Registration Number
- NCT04097574
- Locations
- 🇯🇵
NPO-13 Trial Site 12, Kurume, Fukuoka, Japan
🇯🇵NPO-13 Trial Site 1, Shimotsuke, Tochigi, Japan
🇯🇵NPO-13 Trial Site 2, Maebashi, Gunma, Japan
Study of NPF-08 in Patients Who Receive Colonoscopy
Phase 3
Completed
- Conditions
- Patients Who Receive Colonoscopy
- Interventions
- Drug: NPF-08 （2-day split dose）Drug: Moviprep（1-day treatment）Drug: NPF-08 （1-day treatment）
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Nihon Pharmaceutical Co., Ltd
- Target Recruit Count
- 632
- Registration Number
- NCT03794310
- Locations
- 🇯🇵
NPF-08 Trial Site 2, Chuo-Ku, Tokyo, Japan
🇯🇵NPF-08 Trial Site 5, Yokohama, Kanagawa, Japan
🇯🇵NPF-08 Trial Site 9, Yokohama, Kanagawa, Japan
Phase I/II Clinical Trial of NPF-08 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: NPF-08
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Nihon Pharmaceutical Co., Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT03423771
- Locations
- 🇯🇵
Osaka, Osaka, Japan
Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy
Phase 3
Completed
- Conditions
- Patients Undergoing Gastrointestinal Endoscopy
- Interventions
- Drug: NPO-11Drug: Placebo
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Nihon Pharmaceutical Co., Ltd
- Target Recruit Count
- 220
- Registration Number
- NCT03263910
- Locations
- 🇨🇳
East China, East China, China
Phase Ⅱ Dose Response Study of NPO-13 in Patients Undergoing Total Colonoscopy
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Nihon Pharmaceutical Co., Ltd
- Target Recruit Count
- 132
- Registration Number
- NCT02265939
Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Nihon Pharmaceutical Co., Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT02250391
Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Nihon Pharmaceutical Co., Ltd
- Target Recruit Count
- 22
- Registration Number
- NCT02221271
- Locations
- 🇯🇵
Nihon Pharmaceutical Co., Ltd, Osaka, Japan
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Nihon Pharmaceutical Co., Ltd
- Target Recruit Count
- 7
- Registration Number
- NCT01845584
- Locations
- 🇯🇵
Japan, Osaka,, Japan
Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Nihon Pharmaceutical Co., Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT01827072
- Locations
- 🇯🇵
Nihon Pharmaceutical Co., Ltd, Osaka, Japan
© Copyright 2025. All Rights Reserved by MedPath